A Phase 1 interventional study of Stiripentol capsule (Diacomit®) and Stiripentol oral suspension (Diacomit®) in Dravet Syndrome, Epilepsy and Childhood, sponsored by Biocodex. Completed at 2 sites in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Biocodex · Phase 1, Interventional, and Treatment
This is a Phase I, open-label, randomized, single-center, two-way cross-over study evaluating the relative bioavailability, pharmacokinetics, safety, and palatability of two formulations of stiripentol (Diacomit®), indicated in Dravet syndrome. The investigational products are 500 mg capsules (reference) and a 50 mg/mL oral suspension (test).
The primary objective is to compare the relative bioavailability of the two formulations after a single 1,000 mg oral dose under fed conditions, based on Cmax, AUC0-t, and AUC0-∞. Secondary objectives include other PK parameters (tmax, tlag, ke, t1/2) and characterization of metabolites MIa and MIb. Palatability of the suspension will be assessed by questionnaire.
Safety evaluation will include adverse events, laboratory tests, ECGs, urinalysis, drug and alcohol screening, serology, and vital signs.
Twenty-four healthy volunteers (18-50 years) will be enrolled. Eligibility: BMI 18-30 kg/m², weight ≥50 kg, normal ECG and labs, and informed consent. Women of childbearing potential must use effective contraception and test negative for pregnancy. Exclusions: significant disease, recent surgery or blood donation, hypersensitivity, difficulty swallowing, use of CYP modulators (e.g., carbamazepine, grapefruit, herbal products), drug or alcohol abuse, smoking >5 cigarettes/day, or inability to follow dietary restrictions. Subjects testing positive for HIV, HBV, HCV, or drugs of abuse will also be excluded.
Each participant will attend a screening visit within 28 days before dosing, then two 3-day hospitalizations separated by a 7-15-day washout. On Day 1 of each period, they will receive either two capsules (1,000 mg) or 20 mL suspension (1,000 mg). Blood will be collected at 36 timepoints (≈180 mL total) for PK assessment.
The total study duration per subject is about seven weeks, including screening, hospitalization, dosing, washout, and follow-up. Treatment consists of one dosing day per period.
Sample size was based on prior data: 21 pairs provide 80% power for bioequivalence within 0.80-1.25 bounds; 24 subjects will be recruited to account for dropouts. Analyses will include the Safety Set, PK Concentrations Set, and PK Analysis Set.
This trial aims to establish whether the oral suspension provides a PK profile comparable to capsules, while generating safety, tolerability, and palatability data to support a more convenient formulation for Dravet syndrome patients.
Stiripentol (Diacomit®) is currently marketed in two dosage forms: capsules (250 and 500 mg) and powder for oral suspension in sachets (250 and 500 mg). The powder formulation was developed for patients unable to swallow capsules. A previous study in healthy volunteers demonstrated that the capsule and sachet formulations were bioequivalent in terms of AUC but not Cmax. The Cmax of the sachet formulation was approximately 23% higher than that of the capsule, outside the accepted bioequivalence range. As a result, clinical supervision is recommended when switching between capsule and sachet formulations.
According to the European Summary of Product Characteristics (SmPC), stiripentol dosage escalation should be gradual, starting at 20 mg/kg/day and increasing stepwise depending on age. Dravet syndrome typically begins in infancy, and early initiation of antiepileptic treatment is recommended. A new oral suspension formulation (50 mg/mL) has been developed to facilitate flexible dose adjustments and accurate administration in pediatric patients, especially infants, where precise titration is essential.
This clinical study aims to compare the relative bioavailability of the new oral suspension (test formulation) to the capsule (reference formulation) after a single 1,000 mg dose under fed conditions. In addition to pharmacokinetic endpoints, safety, tolerability, and palatability will be assessed in healthy volunteers. The results will provide critical information on whether the new suspension offers a pharmacokinetic profile comparable to the capsule while improving dosing flexibility and patient convenience in clinical practice.
87 studies on the registry are indexed under Epilepsies, Myoclonic; 23 are open to participants now.
This study's enrollment of 24 is close to the median of 25 across 54 interventional studies indexed under Epilepsies, Myoclonic.
Browse Epilepsies, Myoclonic studies →Biocodex is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Subjects randomized to Sequence A will receive a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) in Period 2 after a 7-15 day
Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)
Subjects randomized to Sequence B will receive a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) in Period 2 after a 7-15 day washout.
Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)
Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.
Also known as: Stiripentol 500 mg capsule, Diacomit® capsule
Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.
Also known as: Stiripentol 50 mg/mL suspension, Diacomit® oral suspension
Relative bioavailability of stiripentol oral suspension (50 mg/mL) vs capsule (500 mg) after a single 1,000 mg oral dose with food, assessed by PK parameters Cmax, AUC0-t, and AUC0-∞ using plasma LC-MS.
The relative bioavailability of stiripentol oral suspension (50 mg/mL) versus capsule (500 mg) after a single 1,000 mg oral dose under fed conditions. It will be assessed by calculating geometric mean ratios with 90% confidence intervals for the main pharmacokinetic parameters: maximum observed plasma concentration (Cmax), area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t), and area under the concentration-time curve extrapolated to infinity (AUC0-∞). Plasma concentrations of stiripentol will be measured using validated liquid chromatography-mass spectrometry (LC-MS) methods to ensure accuracy and reliability of the pharmacokinetic evaluation.
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Time to maximum concentration (tmax)
Time frame: Up to 36 hours post-dose (per period).
Safety and tolerability of stiripentol
Number, nature, incidence, seriousness, severity, and resolution of adverse events following single-dose administration.
Time frame: From dosing to end of study (~7 weeks per participant).
Palatability of stiripentol oral suspension
Assessed using a self-administered palatability questionnaire completed 20 minutes after administration of the oral suspension
Time frame: 20 minutes after administration of the oral suspension
Other PK parameters of stiripentol
Time before start of absorption (tlag)
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Elimination rate constant (ke)
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Terminal half-life (t1/2)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Maximum concentration (Cmax)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Area under the curve from time 0 (pre-dose) to the last measurable concentration (AUC0-t)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Area under the curve from time 0 (pre-dose) to infinity (AUC0-∞)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Time of occurrence of maximum concentration (tmax)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Elimination rate constant (ke)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Apparent terminal elimination half-life (t1/2) measured from plasma concentrations using Liquid chromatography-mass spectrometry (LC-MS)
Time frame: Up to 36 hours post-dose (per period)
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biocodex